Detalhe da pesquisa
1.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(8): 1031-1043, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35810754
2.
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.
Haematologica
; 106(9): 2354-2363, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054121
3.
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
Br J Haematol
; 175(5): 884-891, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27682187
4.
The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age.
Cancers (Basel)
; 15(13)2023 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37444579
5.
The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program.
Clin Lymphoma Myeloma Leuk
; 22(6): 405-415, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34933827
6.
Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
Med Sci Monit
; 8(4): PI31-6, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-11951079
7.
Modulation of the activity of calcium-activated neutral proteases (calpains) in chronic lymphocytic leukemia (B-CLL) cells.
Blood
; 100(5): 1802-9, 2002 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12176903